The Highly Anticipated FDA Approvals of Galderma's Nemolizumab and Eli Lilly's ... - Markets Insider
Dupixent's dominance in the atopic dermatitis market is waning due to new treatments like Adbry, Cibinqo, and Rinvoq. Dermatologists estimate advanced systemic treatments now serve two-fifths of adult AD patients, highlighting the need for new options. Efficacy attributes like itch reduction and mechanism of action are key differentiators, with nemolizumab and lebrikizumab expected to further shift preferences away from Dupixent.
Highlighted Terms
Related News
Dupixent's dominance in atopic dermatitis treatment is diminishing with the rise of competitors like Adbry, Cibinqo, and Rinvoq. Dermatologists anticipate adopting nemolizumab and lebrikizumab, further challenging Dupixent's market share.
Despite declining use of Sanofi/Regeneron’s Dupixent due to competition from LEO’s Adbry, Pfizer’s Cibinqo, and AbbVie’s Rinvoq, the overall population receiving advanced treatments for atopic dermatitis is rising, according to Spherix Global Insights. Dermatologists estimate that two-fifths of adult atopic dermatitis patients now receive advanced systemic treatments, highlighting the demand for effective AD treatments. The potential approvals of Galderma’s nemolizumab and Eli Lilly’s lebrikizumab could further shift physician preferences, with nemolizumab expected to gain more adoption than lebrikizumab.
Dupixent's dominance in the atopic dermatitis market is waning due to new treatments like Adbry, Cibinqo, and Rinvoq. Dermatologists estimate advanced systemic treatments now serve two-fifths of adult AD patients, highlighting the need for new options. Efficacy attributes like itch reduction and mechanism of action are key differentiators, with nemolizumab and lebrikizumab expected to further shift preferences away from Dupixent.